Clinical Trial

Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)

Study acronym: CALM-R
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 12, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.
Trial Details
NCT Number NCT07333885
Lead Sponsor Phynova Group Ltd
Collaborators: People Science, Inc.
Conditions Glycemic Response, Menopause Symptoms
Enrollment 120 participants
Start Date 2025-12-12
Primary Completion 2026-06 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-12